Medtronic (MDT) Q2 FY2025 earnings: revenue $8.4 billion, up 5.2% on the year
Medtronic plc (MDT) reported revenue of $8.4 billion for Q2 FY2025, the quarter ended 25 October 2024, up 5.2% on the same quarter a year earlier. Net income was $1.3 billion, up 39.7% on the year, and diluted earnings per share $0.99. The figures are the company's own, from the 10-Q it filed with the SEC on 26 November 2024.
Revenue
$8.4 billion
+5.2% on the year · +6.2% on the quarter
Q3 FY2023Q2 FY2025
Operating margin
19.0%
16.8% a year earlier
Q3 FY2023Q2 FY2025
Net income
$1.3 billion
+39.7% on the year · +21.9% on the quarter
Q3 FY2023Q2 FY2025
Diluted EPS
$0.99
+45.6% on the year · +23.7% on the quarter
Q3 FY2023Q2 FY2025
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
$ million
Q2 FY2025
Q1 FY2025
Q2 FY2024
On the quarter
On the year
Last 8 quarters
Revenue
8,403
7,915
7,984
+6.2%
+5.2%
Cost of revenue
2,946
2,761
2,761
+6.7%
+6.7%
Gross profit
5,457
5,154
5,223
+5.9%
+4.5%
Gross margin
64.9%
65.1%
65.4%
Research and development
697
676
698
+3.1%
-0.1%
Selling, general and administrative
2,757
2,655
2,686
+3.8%
+2.6%
Operating income
1,595
1,278
1,340
+24.8%
+19.0%
Operating margin
19.0%
16.1%
16.8%
Interest expense
209
167
180
+25.1%
+16.1%
Pre-tax income
1,559
1,268
1,313
+22.9%
+18.7%
Income tax
281
220
402
+27.7%
-30.1%
Effective tax rate
18.0%
17.4%
30.6%
Net income
1,270
1,042
909
+21.9%
+39.7%
Net margin
15.1%
13.2%
11.4%
Diluted EPS
$0.99
$0.80
$0.68
+23.7%
+45.6%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q2 FY2025
Q1 FY2025
Q2 FY2024
On the quarter
On the year
Last 8 quarters
Operating cash flow
958
986
661
-2.8%
+44.9%
Capital expenditure
404
520
461
-22.3%
-12.4%
Free cash flow
554
466
200
+18.9%
+177.0%
Free cash flow margin
6.6%
5.9%
2.5%
Cash from investing
-345
-259
-424
Cash from financing
-534
-731
-90.0
Depreciation and amortisation
675
662
672
+2.0%
+0.4%
Share-based compensation
159
83.0
146
+91.6%
+8.9%
Buybacks
288
2,492
226
-88.4%
+27.4%
Dividends paid
897
898
918
-0.1%
-2.3%
Dividend per share
$0.70
$0.70
$0.69
0.0%
+1.4%
Diluted shares, weighted
1,287m
1,296m
1,332m
-0.7%
-3.4%
Shares outstanding at period end
1,283m
1,282m
1,330m
+0.0%
-3.6%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q2 FY2025
Q1 FY2025
Q2 FY2024
On the quarter
On the year
Last 8 quarters
Shareholders' equity
48,494
47,947
51,460
+1.1%
-5.8%
Non-controlling interest
222
213
187
+4.2%
+18.7%
Debt
28,326
27,865
25,080
+1.7%
+12.9%
Finance lease liabilities
50.0
52.0
56.0
-3.8%
-10.7%
Other liabilities
12,950
13,672
13,304
-5.3%
-2.7%
Total liabilities and equity
90,042
89,749
90,087
+0.3%
-0.0%
Fixed assets
6,438
6,282
5,735
+2.5%
+12.3%
Goodwill
41,161
41,084
40,821
+0.2%
+0.8%
Intangible assets
12,423
12,819
14,060
-3.1%
-11.6%
Investments
6,595
6,532
6,423
+1.0%
+2.7%
Cash and equivalents
1,394
1,311
1,311
+6.3%
+6.3%
Receivables
6,260
6,011
5,934
+4.1%
+5.5%
Inventory
5,479
5,414
5,754
+1.2%
-4.8%
Other assets
10,292
10,296
10,049
-0.0%
+2.4%
Total assets
90,042
89,749
90,087
+0.3%
-0.0%
Questions
What was Medtronic's revenue in Q2 FY2025?
Medtronic (MDT) reported revenue of $8.4 billion for Q2 FY2025, the quarter ended 25 October 2024, up 5.2% on the same quarter a year earlier.
How much did Medtronic earn in Q2 FY2025?
Net income for Q2 FY2025 was $1.3 billion, up 39.7% on the year, and diluted earnings per share $0.99.
When did Medtronic report Q2 FY2025 results?
Medtronic filed its 10-Q for the quarter ended 25 October 2024 with the SEC on 26 November 2024.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 25 October 2024, filed 26 November 2024: the filing.